Orphazyme AS (CHIX:ORPHAC) Additional Paid-In Capital : kr2,087.44 Mil(As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Additional Paid-In Capital?

Orphazyme AS's quarterly additional paid-in capital stayed the same from Jun. 2021 (kr2,082.49 Mil) to Dec. 2021 (kr2,082.49 Mil) but then increased from Dec. 2021 (kr2,082.49 Mil) to Jun. 2022 (kr2,087.44 Mil).

Orphazyme AS's annual additional paid-in capital increased from Dec. 2019 (kr924.02 Mil) to Dec. 2020 (kr2,082.25 Mil) and increased from Dec. 2020 (kr2,082.25 Mil) to Dec. 2021 (kr2,082.49 Mil).

Orphazyme AS Additional Paid-In Capital Historical Data

The historical data trend for Orphazyme AS's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Additional Paid-In Capital Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

Get a 7-Day Free Trial

924.02

2,082.25

2,082.49

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Additional Paid-In Capital	Get a 7-Day Free Trial									1,611.63	2,082.25	2,082.49	2,082.49	2,087.44

Orphazyme AS Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Orphazyme AS Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines